119-S-355 Journalist Public Summary

Headline Summary

A bipartisan bill to speed FDA rule changes so non‑animal “nonclinical” tests can count in early drug reviews, with the Senate passing it and the House now holding it at the desk. [1]Congress.gov — Text - S.355 (119th): FDA Modernization Act 3.0[2]Congress.gov — All Info (Except Text) for S.355 — actions, cosponsors, status

What It Does

The bill orders the FDA to publish an interim final rule—within one year of enactment—that swaps outdated references to “animal” tests across FDA’s investigational new drug (IND) regulations with “nonclinical” tests, and adds the definition of “nonclinical test” Congress adopted in 2023. The rule would take effect immediately upon publication. In plain terms: it tells FDA to finish updating its rulebook so companies can use validated non‑animal approaches (alongside other methods) to support starting human trials. [1]Congress.gov — Text - S.355 (119th): FDA Modernization Act 3.0

Who’s For It

• Bipartisan senators: Sponsored by Sen. Cory Booker with nine bipartisan co‑sponsors spanning both parties (e.g., Sens. Paul, Schmitt, King, Kennedy, Whitehouse, Marshall, Blumenthal, Luján, and Schiff), signaling cross‑aisle support for updating FDA rules. [2]Congress.gov — All Info (Except Text) for S.355 — actions, cosponsors, status
• Animal‑welfare advocates: Groups that pushed FDA to prioritize non‑animal methods praised the agency’s 2025 shift and back efforts to lock this approach into regulation (e.g., Humane World Action Fund). [4]Humane World Action Fund — Humane World Action Fund press release praising FDA’…
• Some innovation‑focused scientists and startups favor clearer pathways for “new approach methodologies” (NAMs), arguing these tools can be more predictive for certain questions than traditional animal models; they view regulatory alignment as reducing uncertainty. (Inference based on FDA’s announced NAMs roadmap and stakeholder reactions.) [3]U.S. Food and Drug Administration — FDA press release: Plan to phase out some a…

Who’s Against It

• Biomedical research organizations caution against over‑promising: NABR says there is currently no full replacement for animal models and warns that patient safety could be at risk if unvalidated methods are over‑used. [5]National Association for Biomedical Research — NABR statement on reducing anima…
• Context from prior law (2022): NABR emphasized that earlier reforms (FDA Modernization Act 2.0) did not eliminate animal testing and urged careful validation of alternatives—sentiments likely to shape their view of this follow‑on bill. [6]National Association for Biomedical Research — NABR press statement on FDA Mode…

What’s Next

Process-wise, the bill passed the Senate by unanimous consent on December 16, 2025, was received in the House on December 17, and is currently held at the House desk. The House can take it up, refer it to committee, or act by unanimous consent; if it passes the House, it would go to the President. [2]Congress.gov — All Info (Except Text) for S.355 — actions, cosponsors, status

Tone